Genprex completes 0.09 mg/kg dose in Phase 1 Acclaim-3 trial; SRC approves escalation to highest dose

Genprex, Inc.

Completed 0.09 mg/kg dose group of Reqorsa + Tecentriq in ES-SCLC Phase 1; no dose-limiting toxicities reported.
Safety Review Committee approved escalation to 0.12 mg/kg, the highest planned dose group.
Phase 2 expansion will enroll 50 patients at 10-15 U.S. sites; primary endpoint is 18-week PFS rate.
Acclaim-3 has FDA Fast Track and Orphan Drug Designations for this patient population.
Company expects to start Phase 2 expansion in H2 2024, pending enrollment in the 0.12 mg/kg cohort.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.